Researchers from the Department of Veterinary Medicine have developed an innovative new antibody-based therapy that could transform how bacterial infections are treated, offering fresh hope in the global fight against antimicrobial resistance (AMR).
Published in Science Translational Medicine, the study presents an innovative new antibody technology known as Targeted Complement Activation Therapy (T-CAT), designed to help the immune system more effectively identify and destroy harmful bacteria - including multidrug-resistant pathogens.
As antimicrobial resistance continues to rise worldwide, there is an urgent need for new treatments that can tackle dangerous bacterial infections without contributing to further drug resistance. Monoclonal antibodies have shown promise in treating infectious diseases, but bacterial infections present a unique challenge. Unlike viruses, bacteria have evolved sophisticated ways to evade immune responses, making them harder to eliminate.
The newly developed T-CAT approach overcomes this problem by enhancing the body’s natural immune defence mechanisms. Rather than relying on conventional antibody activity alone, T-CAT antibodies are engineered to directly trigger the complement system - a powerful part of the immune response responsible for marking and destroying invading pathogens.
By effectively bypassing the bacterial defence strategies that normally block complement activation, T-CAT enables rapid and targeted immune clearance of infection.
The researchers demonstrated that T-CAT antibodies significantly improved bacterial killing in laboratory studies and successfully treated severe infections in multiple experimental models of sepsis and pneumonia.
Importantly, the platform showed efficacy against several major bacterial pathogens responsible for serious disease in both humans and animals, including Klebsiella pneumoniae, Pseudomonas aeruginosa, Streptococcus pneumoniae, and Neisseria meningitidis.
These findings highlight the potential of T-CAT as a powerful new treatment approach for bacterial infections, particularly those caused by antibiotic-resistant organisms.
Beyond bacterial infections, the study suggests this technology could have much wider applications, potentially opening new avenues for treating other infectious diseases and conditions where targeted immune activation could improve disease clearance.